GlassScriptPhysician profile
Gene L Tran
NPI 1003094046
$35,569.86
in general payments reported to CMS, 2019-2025
19 companies · $7,784 in 2025
The $7,784 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $527 · 2021: $6,814 · 2022: $8,576 · 2023: $5,256 · 2024: $5,847 · 2025: $7,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,422 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,307.50 |
| Food and Beverage | $2,421.93 |
| Education | $157.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,721.53 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $8,451.53 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $729.98 | 2019-2024 | Uplizna |
| Allergan, INC. | $689.15 | 2019-2021 | |
| Emd Serono, INC. | $608.25 | 2019-2025 | Mavenclad |
| Abbott Laboratories | $253.07 | 2021-2025 | Infinity |
| Harmony Biosciences LLC | $193.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $171.21 | 2019-2023 | |
| Zimmer Biomet Holdings, INC. | $161.75 | 2025 | Accufill |
| Biohaven Pharmaceutical Holding Company LTD. | $131.12 | 2022 | |
| Lilly USA, LLC | $110.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $90.22 | 2021 | |
| Pfizer INC. | $78.75 | 2025 | |
| Supernus Pharmaceuticals, INC. | $59.81 | 2019 | |
| Ucb, INC. | $32.50 | 2025 | Zilbrysq, Rystiggo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $32.40 | 2019 | |
| Organon LLC | $20.34 | 2022 | |
| Horizon Therapeutics Plc | $20.18 | 2021 | |
| Dexcom, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.